Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of WT4869 in Advanced Solid Malignancies
jRCT2080221527Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2011
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of WT4869 in Non-hematologic malignancy (2 cohorts), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of WT4869 and Maximum tolerated dose (MTD) of WT4869. Started Jul 2011; status: completed.
02
Drugs
WT4869
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080221527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221527.